文献速递冠心病血脂与心血管预防

慢性肾脏病合并急性冠脉综合征患者的P2Y12-ADP受体阻断治疗

P2Y12-ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes.
PubMed 文献 · Circulation · 2018-01-01

综述探讨慢性肾脏病(CKD)患者急性冠脉综合征(ACS)时缺血与出血风险增高的病理生理机制,以及新型口服P2Y12-ADP受体拮抗剂(普拉格雷、替格瑞洛)的风险获益比。CKD患者常被排除在大型临床试验之外,且循证治疗(包括血运重建和现代抗血小板治疗)使用不足。现有证据多来自大型随机试验的亚组分析,其中4期和透析患者罕见。

要点

  • CKD患者ACS后缺血和出血风险均增高,与凝血 cascade 和血小板聚集改变有关。
  • 普拉格雷和替格瑞洛较氯吡格雷抗血小板作用更强,但CKD患者专用试验缺乏。
  • 现有证据多来自大型随机试验亚组分析,4期和透析患者代表性不足。

核心结论

  • CKD合并ACS患者缺血和出血风险高,新型P2Y12抑制剂的风险获益比尚缺乏专用试验验证。

研究设计与样本

  • 综述,总结CKD患者高缺血和出血风险的机制及强效抗血小板药物在ACS中的风险获益比。

主要发现

  • CKD与加速和严重的动脉粥样硬化血栓性疾病相关,涉及血管 milieu 改变、凝血 cascade 和血小板聚集 alterations。
  • CKD患者常被排除在大型临床试验之外,抗血栓治疗证据多来自亚组分析,4期和透析患者罕见。
  • CKD患者循证治疗包括血运重建和现代抗血小板治疗常使用不足。

临床怎么用

  • 临床医生应认识到CKD合并ACS患者缺血和出血风险均高,需权衡抗血小板治疗的风险获益。
  • 现有证据不支持对CKD 4期和透析患者常规使用强效P2Y12抑制剂,需个体化决策。

局限性

  • 缺乏CKD患者(尤其4期和透析)的专用随机对照试验,现有证据多来自亚组分析。
  • CKD患者在大型临床试验中常被排除或代表性不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Because of its high prevalence, chronic kidney disease (CKD) remains a major health hazard throughout the world. Patients with CKD have a high prevalence and incidence of acute coronary syndromes (ACS). Despite decades of improved care, their higher risk profile persists and cardiovascular diseases remain their leading cause of death. Along with the reduction of glomerular filtration rate, several physiological processes are impacted and participate in the pathophysiology of ischemic and bleeding events. CKD is associated with an accelerated and severe course of atherothrombotic disease, and this relates to a modified vascular milieu with alterations on the level of the coagulation cascade and platelet aggregation. In addition, pharmacokinetics of several drugs, in particular antithrombotics, are altered and differ from that of non-CKD patients. Patients with CKD therefore represent a challenging population for both physicians and researchers. In addition to these perturbations of physiological processes, CKD patients face 2 major issues. First, there is a clear gap in scientific research as they are commonly underrepresented or excluded from major clinical trials. This is particularly true regarding antithrombotic treatment during ACS. Second, there is a gap in offering evidence-based treatment for these patients including state-of-the art options for revascularization and modern antiplatelet treatment, both of which are commonly underused. During the last decade, new potent oral P2Y12-ADP receptor antagonists, prasugrel and ticagrelor, which are more potent antiplatelet agents compared with clopidogrel, were introduced for ACS treatment. However, despite the fact that CKD patients represent a large proportion of those experiencing an ACS and are considered at high risk, there is a lack of dedicated trials and we are left with subgroup analysis of large randomized clinical trials were stage 4 and dialysis patients were rare. In the present review we summarize the mechanisms involved in the high ischemic and bleeding risk of CKD patients and the risk-benefit ratio of potent antiplatelet drugs during ACS.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Bonello L, Angiolillo DJ, Aradi D, et al. P2Y12-ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes. Circulation. 2018. PMID: 30354508. doi:10.1161/CIRCULATIONAHA.118.032078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。